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Introduction
The random nature of T-cell receptor (TCR) generation
inevitably leads to the appearance of deleterious autoreac-
tive clones, but the vast majority of such cells are purged
in the thymus during negative selection. However, there is
abundant evidence showing that significant numbers of
autoreactive cells can ‘slip through the net’ of central toler-
ance into the periphery and thereby potentially mediate
autoimmunity. This phenomenon can be readily demon-
strated by the experimental induction of autoimmunity
when otherwise normal animals are injected with self pro-
teins plus a strong adjuvant [1].
The fact that healthy animals harbour such destructive
cells implies the existence of mechanisms operating in
the periphery that are able to effectively prevent their
activation. Experimental evidence has indeed revealed
numerous avenues by which this can occur, among
them immune ignorance, peripheral deletion/anergy, and
dominant suppression (reviewed in [2]). The existence
of a specific T cell subset that could dominantly sup-
press immune responses was first proposed by
Gershon and Kondo in 1970 [3]. The concept devel-
oped from experiments suggesting that tolerance was
an active cell-mediated process and could be trans-
ferred into naïve animals. Elaborate circuits involving
suppressor, contrasuppressor and veto cells were pro-
posed to explain the maintenance of self-tolerance;
however, the inability to clone any actual suppressor
cells or identify critical molecules associated with them
led to the decline of such a model. Furthermore, the
subsequent emergence of the Th1–Th2 paradigm
seemed largely able to subsume suppression phenom-
ena by the patterns of regulatory cytokines that these
cells could secrete, and the parsimony thus offered
seemed much more attractive as a theory.
In contrast, accumulated evidence from the mid-1980s
has shown that depletion of a particular T cell subset from
normal animals can cause autoimmune disease similar to
the counterparts in humans, and that reconstitution of this
subset can prevent these diseases. Subsequent detailed
phenotypic characterisation of such autoimmune preventa-
tive cells now leaves no doubt of the existence of TR cells
as crucial mediators of self-tolerance in both animal
models and humans.
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Abstract
The interest in naturally arising regulatory T (TR) cells as a paradigm for maintaining immunological self-
tolerance has undergone an explosive re-emergence in recent years. This renaissance was triggered
by several key experimental observations and the identification of specific molecular markers that have
enabled the isolation and experimental manipulation of these cells. Although their existence was once
controversial, a large body of evidence now highlights the critical roles of TR cells in maintaining
immunological self-tolerance. Furthermore, abnormality of natural TR cells can be a primary cause of
autoimmune and other inflammatory diseases in humans.
Keywords: CD25+CD4+, Foxp3, regulatory cells, self-tolerance, suppression20
Arthritis Research & Therapy    Vol 6 No 1 Fehérvári and Sakaguchi
Defining a ‘regulatory cell’
Broadly speaking, T cells with regulatory properties can be
divided into two types: naturally occurring thymically gen-
erated regulatory cells, defined here as ‘TR cells’, and
those generated by antigenic stimulation under special
conditions in the periphery, referred to variously as ‘Th3’,
‘Tr1’ cells or ‘adaptive regulatory cells’ (see, for example,
[4]). This review will focus chiefly on the naturally arising
suppressive TR cells.
A discrete molecular description of TR cells has proved to
be a key issue in this field and was indeed one of the major
stumbling blocks to their original exposition. Early clues
hinting at the identity of regulatory cells emerged from
experimental models of autoimmune disease. Many such
models require the induction of lymphopoenia in genetically
susceptible strains of rodents, for example 3-day-old
neonatal thymectomy or adult thymectomy coupled with an
immunosuppressive treatment such as cyclophosphamide
[5–7]. Depending on the strain background, experimental
manipulations of this kind result in a variety of autoimmune
diseases such as thyroiditis, gastritis, oophoritis and orchi-
tis. It was subsequently shown that induction of such
autoimmunity could be prevented by the transfer of normal
CD4+ splenocytes or CD4+CD8– thymocytes [7–10]. Col-
lectively, such data strongly suggested that a cell popula-
tion with a crucial role in maintaining self-tolerance was
resident within the normal T lymphocyte pool.
Attempts were then made to phenotype putative TR cells
more specifically by isolating the T lymphocyte fraction
that harboured regulatory activity. Sakaguchi and col-
leagues managed to first identify the CD5 molecule as a
marker for TR cells by demonstrating that otherwise normal
lymphocytes depleted of CD5highCD4+ cells induced
broad-spectrum autoimmunity when transferred into
athymic nude mice [11]. Unfractionated CD4+ cells
(which contain CD5high-expressing cells) prevented the
induction of autoimmunity when transferred together with
the CD5low cells, implying that the TR cells were contained
specifically within the CD5high compartment. Subsequent
experiments aimed at homing in yet further on TR cell-spe-
cific markers have identified a number of other potential
candidate molecules. For instance, CD45RB seems to
divide T cells into two distinct functional subsets [12].
Lymphopoenic mice transferred with CD45RBhigh cells
develop a lethal wasting disease characterised by severe
inflammatory bowel disease (IBD), whereas unfractionated
T cells or CD45RBlow cells alone cause no disease. Impor-
tantly, co-transfer of the CD45RBlow and CD45RBhigh
populations results in protection of the mice from colitis.
More recently, the most useful surface marker for TR cells
has proved to be the interleukin-2 (IL-2) receptor α-chain,
CD25 [13]. About 5–10% of CD4+ T cells and less than
1% of CD8+ peripheral T cells constitutively express
CD25 in normal naïve mice, and such cells are found in
the CD5high and CD45RBlow T cell fractions. Indeed, trans-
fer of CD25-depleted CD4+ T cells to athymic mice
results in a variety of autoimmune diseases, whereas
transfer with CD25+CD4+ cells inhibits such disease
development. Moreover, CD25+CD4+ cells in normal
naïve mice exhibit clear immunosuppressive properties in
vitro and in vivo [13,14]. It now seems that the naturally
occurring CD25+CD4+ population could account for the
regulatory effect of CD5high and CD45RBlow CD4+ T cells.
A comprehensive characterisation of the surface profile of
TR cells has revealed them to be quite distinct from con-
ventional naïve effector T cells. Aside from the constitutive
expression of CD25, TR cells show elevated levels of
adhesion molecules such as CD11a (LFA-1), CD44,
CD54 (ICAM-1), CD103 (αEβ7 integrin) in the absence of
any apparent exogenous antigenic stimulation [14,15].
Naturally occurring CD25+CD4+ cells additionally express
CD152 (CTLA-4), a molecule classically only expressed
after T cell activation [16–18]. There is some evidence to
suggest that TR cells might also exhibit a characteristic
chemokine receptor profile, with mouse CD25+CD4+ cells
expressing elevated levels of CCR5 and their human
counterparts expressing CCR4 and CCR8 [19,20]. Such
a distinctive pattern of chemokine receptors suggests that
TR cells might be rapidly recruited to sites of inflammation
and thereby efficiently control immune responses. Most
recently, several groups have demonstrated that glucocor-
ticoid-induced tumour necrosis factor family related
protein (GITR) is predominantly expressed at both the
RNA and protein levels by CD25+CD4+ cells [15,21,22].
Administration of the anti-GITR monoclonal antibody,
DTA-1, in vivo elicits autoimmune disease, suggesting that
this molecule has an important functional role in maintain-
ing TR cell suppression [22].
The surface marker profile of TR cells is thus quite different
from that of naïve T cells. However, it should be noted that
most, if not all, of their apparently characteristic molecules
are upregulated during conventional T cell activation. This
similarity to otherwise normal but primed T cells is poten-
tially problematic when trying to identify or isolate true
TR cells and precludes the use of CD25 alone (or any other
surface molecule yet found) as an infallible marker. This
caveat aside, several important distinctions still remain
between the surface phenotype of TR and primed T cells,
but they are more relative than absolute. For example,
although both primed T cells and TR cells express CD25,
the latter does so to a higher level and more stably. Indeed,
when stimulation of normal T cells ceases, CD25 expres-
sion is lost, whereas TR cells revert to their original constitu-
tive expression level [23]. In addition, CD25+ cells
generated from originally CD25–CD4+ cells show no sup-
pressive ability either in vitro or in vivo [23]. As a compo-
nent of the high-affinity IL-2 receptor, CD25 itself is21
essential for the survival of TR cells, and the cells are
exquisitely sensitive to an absence of signalling through
this receptor [24]. Clear evidence for this can be seen by
the almost total absence of CD25+CD4+ cells in IL-2-defi-
cient mice. In conclusion, the similarities between TR cells
and primed T cells are therefore probably only a reflection
of a shared activation state.
As noted above, the search for a definitive TR cell marker
has been fraught with complications and an occasional
lack of certitude regarding their undeniable existence as a
functionally distinct population rather than simply another
activation state of conventional T cells. However, some
very recent data have gone some way to demonstrating
conclusively that TR cells are a genuine T cell lineage, in
the process identifying a seemingly unambiguous marker
[25–27]. Studies with the Scurfy (sf) mutant mouse model
provided the required breakthrough. The Scurfy mouse
exhibits a fatal X-linked lymphoproliferative disease that is
mediated by highly activated CD4+ T cells and is akin to
the phenotype of both CTLA-4 and transforming growth
factor (TGF)-β knockout mice [28–32]. Subsequent work
mapped the sf mutation to a novel forkhead/winged-helix
family transcriptional repressor termed Foxp3, which
encodes the protein scurfin [33]. A mutation in the human
orthologue, FOXP3, has also been identified as the under-
lying cause of the aggressive autoimmune syndrome IPEX
(for Immune dysregulation, Polyendocrinopathy, Enteropa-
thy, X-linked syndrome) [33–35].
The overt immunological similarities seen with genetic
defects of Foxp3 and the experimental depletion of
CD25+CD4+ TR cells led several groups to investigate the
potential role of Foxp3 in the development and function of
TR cells. Three independent groups were able to demon-
strate that Foxp3 mRNA [25–27] and the encoded protein
[27] were specifically expressed only in naturally arising
CD25+CD4+ TR cells and, critically, were never observed
in normal T cells even after they had been activated and
acquired the expression of CD25/GITR. However, a very
low level of Foxp3 expression was observed in
CD25–CD4+ T cells; this appeared to be attributable to a
small population of CD25–CD45RBlowGITRhigh TR cells
([26], M Ono, manuscript in preparation). In addition,
TR cells were unable to develop in the absence of Foxp3,
as demonstrated by the use of sf mice or by the targeted
deletion of Foxp3 [25,27]. Finally, and most convincingly,
retroviral transduction of Foxp3 into conventional CD25–
Foxp3– T cells converted them into phenotypical and func-
tional TR cells capable of effectively suppressing both in
vitro and  in vivo [26,27]. Thus Foxp3 seems to be a
‘master gene’ controlling the normal development and/or
function of naturally occurring TR cells.
As yet there are very few data detailing the role and expres-
sion patterns of FOXP3 in human cells. Some of the early
indications, both published and unpublished, have shown
FOXP3 expression in human CD25+CD4+ T cells ([36], H
Yagi and S Sakaguchi, unpublished results); however, it
already seems that there are some discrepancies with the
murine data. For example, there seem to be considerable dif-
ferences in FOXP3 expression between individuals and,
more significantly, FOXP3 might be inducible in human
CD25–CD4+ cells (which start off apparently FOXP3–) after
anti-CD3/anti-CD28 stimulation [36]. It remains to be deter-
mined whether this simply represents an expansion to
detectability of the tiny Foxp3+GITR+CD25–CD4+ popula-
tion described above ([26], M Ono, manuscript in prepara-
tion) or is a genuine property of human T cells radically
different from that of mice.
The suppressive properties of TR cells can be modelled in
vitro by mixing titrated numbers of highly purified
CD25+CD4+ cells and CD25–CD4+ (or CD25–CD8+)
responder cells plus a TCR stimulus such as anti-CD3,
ConA or antigen-presenting cells (APCs) plus antigenic
peptide. Under such conditions, the CD25+ population
suppresses both the proliferation and IL-2 production of
the CD25– cells in a dose-dependent manner [37,38].
The TR cells require TCR stimulation to exert any suppres-
sive effects, but once this condition has been satisfied the
ensuing suppression is non-specific for antigen [37,38].
Suppression is therefore an active process and can be
directed against bystander cells.
Curiously, the CD25+CD4+ TR cells themselves are
anergic in vitro; that is, they do not proliferate or produce
IL-2 in response to conventional T cell stimuli. However,
this anergy can be broken by a sufficiently potent stimulus
such as the addition of exogenous IL-2 or anti-CD28, or
the use of mature dendritic cells as APCs [37,39]. Inter-
estingly, anergy seems to be the default state for TR cells,
because they revert to it once IL-2 is withdrawn [37,38].
However, the anergy in vitro is not reflected in vivo,
wherein TR cells seem to have a highly active rate of
turnover [24]. An anergic state also seems to be closely
related to TR cells’ suppressive ability because if it is
broken there is a concomitant loss of regulatory activity
both in vitro and in vivo [37]. Table 1 summarises what is
currently known about the TR cell phenotype.
Development and origin
CD25+CD4+ TR cells are produced by the normal thymus
as fully functioning suppressive cells, and such thymo-
cytes exhibit apparently all the properties of their matured
peripheral counterparts [14]. Itoh and colleagues showed
that the adoptive transfer of CD25-depleted thymocytes to
syngeneic nude mice recipients led to a similar spectrum
of autoimmune disease to that with CD25–CD4+ periph-
eral cells [14]. CD25+CD4+ thymocytes are also anergic
and suppressive in vitro and exhibit a classic TR cell
surface phenotype, for example elevated levels of activa-
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tion markers such as CTLA-4 and GITR; importantly they
are also Foxp3+ [14,22,26].
TR cells can develop in TCR transgenic mice specific for an
exogenous peptide; however, those cells that do develop
show a strong bias for expressing an endogenous TCR-α
chain paired with the transgenic β-chain, in contrast to
CD25–CD4+ cells, which predominantly expressed only
the whole transgenic TCR [14,40]. When these mice were
bred onto a RAG-2–/– or TCRα–/– background (both of
which lack endogenous α-chain gene rearrangements),
CD25+CD4+ cells were eliminated, suggesting that sig-
nalling through TCRs expressing the endogenous
TCRα-chains was necessary for their development [14,40].
Furthermore, studies with a doubly transgenic mouse have
also demonstrated that the CD25+CD4+ TR cells show a
high self-reactivity and differentiate on thymic epithelial
cells [41,42]. Thus, the central generation of CD25+CD4+
TR cells is dependent on relatively high-avidity TCR inter-
actions with self-peptide/MHC complexes within the
thymic stroma. However, it is still not clear why the rela-
tively self-reactive TR cell precursors escape thymic nega-
tive selection and instead begin a developmental
programme involving Foxp3. Although apparently not
required for the activation of suppressive functions, the
classic co-stimulatory molecule CD28 seems to be impor-
tant in the thymic production of TR cells and/or their
peripheral maintenance, as demonstrated by markedly
reduced TR cell numbers in CD28–/– animals [18]. A
similar decrease in the TR cell population could also be
observed by blockading CD28–B7 interactions with
CTLA-4-immunoglobulin fusion protein [18]. Finally,
CD40–CD40L interactions also seem to be important in
the development of TR cells, as shown by their marked
decrease in CD40–/– mice [43].
The extra-thymic generation of TR cells from conventional
CD25–CD4+ cells is still an open question. It is clear that
T cells with regulatory properties and an anergic pheno-
type (such as the aforementioned Tr1 cells) can be gener-
ated in the periphery, but whether these are identical to
naturally occurring TR cells remains to be established.
Several approaches have led to the peripheral generation
of regulatory cells. For instance, activation of conventional
T cells in the presence of TGF-β/IL-10 or with the
immunomodulatory agent 1-α-25-dihydroxyvitamin D3 pro-
duces a suppressive T cell [44,45]. Also of potential inter-
est is the induction of regulatory cells by immature or
‘tolerogenic’ dendritic cells (DCs) [46,47]. Additionally, in
some now classic studies, Qin and colleagues were able
to generate regulatory cells by the administration of non-
depleting anti-CD4 monoclonal antibodies in vivo to
thymectomised mice (reviewed in [48]). A final confirma-
tion of whether such peripherally generated regulatory
cells are contiguous with naturally occurring TR cells or are
simply another T cell activation state will have to await the
assessment of Foxp3 expression. A summary of TR cell
developmental steps is shown in Fig.1.
Mechanisms of suppression
The suppression mechanism of activation-induced regula-
tory cells such as Tr1 cells is based primarily on the secre-
tion of anti-inflammatory cytokines such as IL-10 and
TGF-β (reviewed in [49]). The situation with naturally
occurring TR cells is not nearly so clear-cut and despite
intense interest remains strangely inconclusive. Potential
TR cell suppression mechanisms can basically be divided
into those mediated by secreted factors and those requir-
ing intimate cell–cell contact. Most of the experiments in
vivo examining TR cell suppression have been based on
the murine IBD model described above and have, as with
Tr1 cells, flagged the importance of IL-10 and TGF-β. By
blocking IL-10 signalling in vivo with monoclonal antibod-
ies against the IL-10 receptor, Asseman and colleagues
were able to abrogate the normal IBD-preventative action
of CD45RBlow T cells [50]. The same group was also able
to show that CD45RBlow T cells from IL-10-deficient mice
were unable to prevent colitis and, moreover, were even
colitogenic themselves [50]. The importance of IL-10 in
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Table 1
Comparison of the phenotype of conventional naïve CD4+ T cells and CD4+ regulatory cells (TR)
Conventional naïve helper T cell Natural regulatory T cell (TR)
Foxp3– Foxp3+
CD5low, CD11alow, CD25low, CD38low, CD44low, CD45RBhigh, CD5high, CD11ahigh, CD25high, CD38high, CD44high, CD45RBlow, 
CD54low, CD103εlow, GITRlow CD54high, CD103high, GITRhigh
About 90–95% of splenic CD4+ T cells About 5–10% of splenic CD4+ T cells
Responsive to conventional T cell stimuli Anergic to conventional T cell stimuli
Non-suppressive Suppressive
Many of the distinctions are not absolute; for instance, activated non-regulatory effector T cells express cell surface markers with a pattern similar to
that of TR cells, so such discrimination is possible only with constitutive expression. Currently, expression of Foxp3 seems to be the most accurate
marker for TR cells because this does not vary with the activation state.23
the control of IBD is also implied by the observation that
IL-10–/– mice spontaneously develop IBD even though
these mice are not lymphopoenic [51].
Similarly, several groups have shown that a monoclonal-anti-
body-mediated blockade of TGF-β abrogates TR cell sup-
pressive functions both in vivo and  in vitro [52,53].
Interestingly, TGF-β does not necessarily have to act as a
soluble factor but can be expressed exclusively on the
surface of CD25+CD4+ cells after stimulation through the
TCR and might therefore mediate its effects in a membrane-
proximal manner [53]. The level at which these anti-inflam-
matory cytokines operate to maintain tolerance is also
uncertain, but it might be through the inhibition of APCs or
pathogenic T cells, by maintenance of the TR cell population
and/or by enhancement of their function (reviewed in [54]).
Elucidation of the mechanism of TR cell suppression is
complicated by the fact that most evidence in vitro shifts
the emphasis of suppression to mechanisms solely based
on cell contact. First, anti-IL-10 or anti-TGF-β monoclonal
antibody fails to perturb the suppressive activity of
CD25+CD4+ cells in vitro [54], although the use of soluble
IL-10R seems to have a partial effect [55]. A study showing
the successful neutralisation of suppression with anti-
TGF-β monoclonal antibodies at the same time also
demonstrated the TGF-β to be bound to the cell surface
[53]. Second, culture supernatants from activated
CD25+CD4+ cells show no inherent suppressive ability,
nor is any suppression observed across a semi-permeable
membrane [37,38]. Taken together, the data in vitro thus
seem to obviate the role of not merely IL-10/TGF-β but also
soluble factors in general, suggesting that TR cell suppres-
sion is dependent on close cell–cell contact, although it is
still impossible to discount completely the possibility that
suppression is mediated in an extreme paracrine fashion.
The membrane events that occur during cell contact-
dependent suppression are entirely unclear, but presum-
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Figure 1
A putative scheme for the development of regulatory T (TR) cells. 
TR and naïve conventional helper T cells (Th0) develop within a normal
thymus through the processes of positive and negative selection.
Precursor T cells of relatively high avidity trigger a TR cell developmental
programme involving the activation of Foxp3, whereas T cell receptors
of intermediate avidity yield Th0 cells. Additionally, regulatory cells can
be peripherally generated (for example, Tr1 cells) when activated under
tolerogenic conditions (for example, with immature dendritic cells). As
yet it is unclear whether de facto Foxp3+ TR cells can be generated in
the periphery or whether the Tr1 cells produced from conventional Th0
cells are equivalent to naturally present TR cells. IL, interleukin; TE cell,
effector T cell; TGF, transforming growth factor.
Figure 2
Possible mechanisms of regulatory T (TR) cell suppression. These mechanisms are not necessarily mutually exclusive, and potentially two or more
might act in concert. (a) Antigen-presenting cell (APC)-activated TR cells transduce an unidentified active negative signal to nearby effector T (TE)
cells located on the same APC or an adjacent one. (b) TR cells outcompete TE cells for stimulatory ligands on the APC surface by virtue of their
high expression of adhesion molecules. (c) TR cells modulate the behaviour of the APC so that they become ineffective or suppressive stimulators
of TE cells. (d) CD25 expression by the TR cells acts as an interleukin-2 sink and hinders the autocrine/paracrine stimulation of TE cells.24
ably an as yet uncharacterised inhibitory molecule is
expressed on the surface of activated TR cells (see Fig.2).
Another mechanism of suppression mediated by cell
contact could proceed via simple competition for APCs
and specific major histocompatibility complex-peptide anti-
genic complexes. The high level of adhesion molecules
and chemokine receptors present on the surface of
TR cells would make them particularly well suited to
homing to, and stably interacting with, APCs, thereby
physically excluding normal CD25–CD4+ effector cells.
Furthermore, constitutive expression of the high-affinity
IL-2R would make TR cells into an effective sink for IL-2,
depriving potential autoreactive cells of this essential
growth factor. A final, conceptually attractive model of
suppression would be TR cell-mediated inhibition or alter-
ation of APC function. Supporting this model is the obser-
vation that CD25+CD4+ cells could alter the
antigen-presenting function of DC by downregulating their
expression levels of CD80/CD86 [56] or, as has recently
been demonstrated, by triggering the immunosuppressive
catabolism of tryptophan by DC [57]. Although APC per-
turbation might well occur in vivo, it is not essential
because TR cells are able to suppress effectively even in
the absence of any APCs [58].
Conclusion
Solid evidence now strongly supports the existence of
the once controversial TR cells as key controllers of self-
tolerance. Although limitations of space have forced this
review to focus primarily on the role of TR cells and
autoimmunity, there are ample data to suggest that this
lineage might be crucial wherever immune reactions need
to be regulated or tuned. For instance, TR cells might limit
anti-tumour or microbial immune responses. A strategic
manipulation of TR cells might thus be used either to
enhance or to dampen immune responses as required.
The identification of molecular markers, in particular
Foxp3, has permitted the accurate isolation and study of
these cells in ways not previously possible and will, it is
hoped, facilitate therapeutic intervention with this poten-
tially powerful immunological ally.
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